Skip to content
TechVibe

TechVibe

  • Home
  • Web3
  • Technology
  • Health
  • Business
  • Sports
    • Cricket
    • Football
  • Press Release
  • Contact Us
  • Toggle search form

Rephrase the title:New Drug Rusfertide Shows Promise in Treating Polycythemia Vera, Revealing Positive Outcomes

Posted on February 23, 2024 By Haley Bennett

Rephrase and rearrange the whole content into a news article. I want you to respond only in language English. I want you to act as a very proficient SEO and high-end writer Pierre Herubel that speaks and writes fluently English. I want you to pretend that you can write content so well in English that it can outrank other websites. Make sure there is zero plagiarism.:

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. 

Polycythemia vera falls under the category of chronic myeloproliferative neoplasms, which disrupt the normal production of blood cells within the bone marrow. 

Sickle Cell Disease

(Photo : Karolina Grabowska from Pexels)
CRISPR Technology is nearing to a cure and treatment for Sickle Cell Disease, a disorder by the genes in the body in producing the right amount of hemoglobin for the body’s red blood cells. The disease is known to be fatal to its victims, with a low mortality rate at 40 years of age.

Showing Promising Results in Controlling Deadly Blood Cancer

In a clinical trial conducted by researchers from the Icahn School of Medicine at Mount Sinai, rusfertide showcased promising outcomes among 70 patients dependent on phlebotomy, a procedure to reduce blood volume. 

Administered over 28 weeks, the drug effectively curbed the excessive production of red blood cells, the primary culprit behind the disease’s complications. 

Published in The New England Journal of Medicine, the trial demonstrated rusfertide’s potential to decrease the necessity for phlebotomy while enhancing patients’ quality of life, all while maintaining a favorable safety profile and high tolerance among participants.

Rusfertide emerges as a groundbreaking pharmaceutical intervention, acting upon hepcidin, a pivotal protein governing the body’s iron levels. By augmenting hepcidin levels, rusfertide curtails iron accessibility for red blood cell synthesis, thereby diminishing red blood cell counts and mitigating polycythemia vera symptoms.

Dr. Marina Kremyanskaya, Associate Professor of Medicine and Medical Director for inpatient oncology at The Mount Sinai Hospital, who led the study, expressed optimism about the potential of rusfertide in revolutionizing treatment for polycythemia vera patients.

Dr. Kremyanskaya emphasized its novel mechanism, which restricts iron availability crucial for blood cell production. She underscored the importance of further clinical investigations, suggesting that this injectable agent could offer much-needed relief for patients grappling with the challenges of polycythemia vera management.

Also Read: AI-Powered Wearables Could Identify User’s Mental Health, Well-Being

Polycythemia vera falls under the umbrella of chronic myeloproliferative neoplasms, a spectrum of conditions influencing blood cell production within the bone marrow. Specifically, this disorder entails an overproduction of red blood cells, resulting in blood that is excessively thick and adhesive. 

Consequently, individuals with polycythemia vera face heightened risks of blood clotting, heart attacks, strokes, and other severe complications. This condition is relatively rare, affecting an estimated 1-3 individuals per 100,000 in the United States, typically manifesting in older adults. 

Current treatment modalities encompass aspirin, medications aimed at reducing red blood cell counts, and phlebotomy. Nonetheless, these approaches exhibit limitations and adverse effects, leaving many patients with inadequately managed conditions and unfavorable prognoses.

Findings of the Study

Researchers discovered that rusfertide effectively controlled hematocrit levels below 45% over 28 weeks and outperformed a placebo during a 12-week withdrawal period. Patients with symptoms like itchy skin, night sweats, difficulty concentrating, and fatigue experienced improvements.

Rusfertide mimics hepcidin, a liver-produced hormone regulating iron trafficking. It reduces red blood cell production by blocking iron export to the blood.

Dr. Kremyanskaya emphasizes rusfertide’s potential to sustain hematocrit control and decrease the need for repeat phlebotomies. A phase 3 clinical trial, led by Mount Sinai, aims to confirm its efficacy and explore benefits in other blood disorders.

Related Article: Scientists Create World’s Smallest Moustache With Weird Ingredient: A Red Blood Cell

Written by Inno Flores

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Haley Bennett

I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.

Health Tags:blood cancer, chronic myeloproliferative neoplasm, clinical trial results, Icahn School of Medicine, Mount Sinai, phlebotomy reduction, polycythemia vera treatment, promising drug, Rusfertide

Post navigation

Previous Post: Rephrase the title:Copa America 2024 stadiums: List of host cities, venues for international soccer tournament in USA
Next Post: Rephrase the title:’Only Virat Kohli left’ – Joe Root rises up in the Fab Four list after 31st Test Ton

Related Posts

2023 Black Friday Sale: Top Apple Discounts on M3 MacBook Pro, AirPods Pro 2, Apple Watch, and More Health
Rephrase the title:Fried Rice Syndrome: Unraveling the Truth Behind TikTok’s Latest Viral Scare Health
Rephrase the title:HIV Drug Holds Promise in Preventing COVID-19 Variants, Reveals New Study Health
Rephrase the title:AI Can Help US in Developing War Plans Says Experts Amidst China-Taiwan Tension Health
Useful iOS Blood Sugar-Tracking Apps for iOS Users in 2023 Health
Rephrase the title:FDA Grants Historic Approval for Gene-Editing Treatment in Sickle Cell Disease Health

Recent Posts

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions
  • Mocaverse to Develop Decentralized Social Layer
  • Expansion of Web3 Fueled by Hong Kong’s Financial Secretary

Categories

  • Business
  • Cricket
  • Football
  • Health
  • Press Release
  • Technology
  • Web3

About Us

Welcome to TechVibe9, where the rhythm of technology meets innovation! We are a group of tech enthusiasts on a mission to uncover and showcase the latest in the tech world.

Mail Us : support@techvibe9.com

Latest Post

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions

Helpful Links

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions

Copyright © TechVibe9

Powered by PressBook Masonry Dark